Trastuzumab-TKI combination in HER2-Positive tumors: a FAERS-Based safety profile and multimodal analysis of Tanespimycin’s role in enhancing targeting of the HSP90AA1-PI3K-Akt-mTOR axis
Background This study addresses the safety profiles and molecular mechanisms of trastuzumab monotherapy and its combination with lapatinib, neratinib, and tucatinib for treating HER2-positive tumors. Methods The research integrates a multi-platform approach, including data from the US Food and Drug Administration Adver...